- Home
- PRAX vs APLT Comparison
PRAX vs APLT Comparison
Compare PRAX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- APLT
- Stock Information
- Founded
- PRAX 2015
- APLT 2016
- Country
- PRAX United States
- APLT United States
- Employees
- PRAX N/A
- APLT N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- PRAX Health Care
- APLT Health Care
- Exchange
- PRAX Nasdaq
- APLT Nasdaq
- Market Cap
- PRAX 1.2B
- APLT 971.6M
- IPO Year
- PRAX 2020
- APLT 2019
- Fundamental
- Price
- PRAX $71.76
- APLT $8.69
- Analyst Decision
- PRAX Strong Buy
- APLT Strong Buy
- Analyst Count
- PRAX 9
- APLT 5
- Target Price
- PRAX $146.33
- APLT $12.50
- AVG Volume (30 Days)
- PRAX 317.5K
- APLT 1.8M
- Earning Date
- PRAX 11-06-2024
- APLT 11-07-2024
- Dividend Yield
- PRAX N/A
- APLT N/A
- EPS Growth
- PRAX N/A
- APLT N/A
- EPS
- PRAX N/A
- APLT N/A
- Revenue
- PRAX $1,605,000.00
- APLT N/A
- Revenue This Year
- PRAX N/A
- APLT N/A
- Revenue Next Year
- PRAX N/A
- APLT $3,169.03
- P/E Ratio
- PRAX N/A
- APLT N/A
- Revenue Growth
- PRAX N/A
- APLT N/A
- 52 Week Low
- PRAX $14.25
- APLT $1.79
- 52 Week High
- PRAX $86.93
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- PRAX 48.78
- APLT 46.34
- Support Level
- PRAX $58.84
- APLT $9.44
- Resistance Level
- PRAX $86.93
- APLT $10.62
- Average True Range (ATR)
- PRAX 6.09
- APLT 0.62
- MACD
- PRAX -0.15
- APLT -0.13
- Stochastic Oscillator
- PRAX 46.00
- APLT 14.95
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.